SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced today, that it has raised $22 million in its Series A-2 round that closed December 15, 2018. The company plans to use the capital to accelerate its growth, continue expansion of its operations and advance its novel immunotherapy platform.
“This investment provides a significant boost to our capital strategy as we proceed to Phase 2 clinical trials and accelerate development of commercial targets for Type 1 diabetes, cancer and influenza,” said Eddie J. Sullivan, PhD, SAB’s president CEO and co-founder.
SAB develops immunotherapies from its unique technology platform to create fully-human immunoglobulins without human serum to transform the treatment and prevention of diseases. The company is focused on cancer, autoimmune and infectious diseases targets.
“The oversubscribed raise will enable us to get further along with our pipeline and represents a tremendous amount of confidence in the team and the technology,” Sullivan said.
Since 2014, the company has developed immunotherapies against more than a dozen targets, achieved 100% efficacy in pre-clinical testing, completed successful Phase 1 clinical trials and secured substantial grants, contracts and in-kind services from collaborators including the Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH).
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company developing human immunotherapies to transform the treatment and prevention of diseases from cancer and inflammation to autoimmune and infectious diseases like influenza. SAB is delivering the world’s first large-scale production platform to create fully human immunoglobulins outside of humans. The DiversitAb™ platform is diverse in its ability to produce antibodies for a variety of health conditions. The platform is also scalable and dynamic, enabling the production of large quantities of therapeutics with a shorter development cycle than current methods. For more information, visit www.sabbiotherapeutics.com